Catarina Edfjäll

Catarina Edfjäll is Vice President, Head of Global Regulatory Affairs at CSL Behring, based in Switzerland and has over 20 years of experience in the pharmaceutical industry, including at Shire, Celgene, Actelion, and Hoffmann-La Roche. Catarina has been responsible for obtaining several designations and approvals for orphan drugs in over 40 countries worldwide. Catarina holds a master's degree in biotechnology engineering and a Ph.D. from the University of Basel, Switzerland.

Since many years, Catarina is driven by a strong interest in bringing new treatments to patients with rare and life-threatening diseases. Over the past 15 years she has been involved in several multi-stakeholder organizations with a focus on rare diseases and was one of three industry representatives on EMA's COMP Working Group with Interested Parties for its entire duration (2001-2008). Since 2001 she is an active member of the EFPIA /EuropaBio joint Orphan Drug Task Force. She was a board member of ICORD 2008-2012 and since 2014 she is the treasurer of the ICORD board. Catarina has been an active member and speaker at several conferences since ICORD's inception.